Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05617677 · ClinicalTrials.gov registry record · Phase 3

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

A Phase 3 study of Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 3
Development phase
516
Enrollment target
20
Study locations

NCT05617677 is a Phase 3 study of Systemic Lupus Erythematosus that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 516 participants, above the 375-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05617677, a Phase 3 study of Systemic Lupus Erythematosus, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
516 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.

Conditions Studied

Systemic Lupus Erythematosus

Interventions

  • OTHER Placebo
  • DRUG Deucravacitinib

Study Locations (20)

California

  • Kaiser Permanente - Fontana
  • Local Institution - 0247 - La Mesa
  • Local Institution - 0090 - La Palma
  • Local Institution - 0124 - Los Angeles
  • Local Institution - 0248 - Sacramento
  • Local Institution - 0253 - San Diego
  • Local Institution - 0128 - Santa Barbara

Florida

  • Local Institution - 0249 - Coral Springs
  • Local Institution - 0010 - Gainesville
  • Local Institution - 0087 - Miami
  • Local Institution - 0007 - Orlando
  • Local Institution - 0242 - Plantation
  • Local Institution - 0002 - Tamarac
  • Local Institution - 0165 - Tampa

Arizona

  • Local Institution - 0229 - Phoenix
  • Local Institution - 0193 - Tucson

Alabama

  • Local Institution - 0012 - Birmingham

Colorado

  • Local Institution - 0099 - Denver

Connecticut

  • Local Institution - 0054 - New Haven

Georgia

  • Local Institution - 0204 - Atlanta

Trial Details

FieldValue
Enrollment Target 516 participants
Start Date 2023-01-12
Est. Completion 2028-11-13
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05617677

The ClinicalTrials.gov registry entry for NCT05617677 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 516 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 375-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (38% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05617677 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT05617677 about?

NCT05617677 is a clinical study titled "A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)". The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.

What is the current status of trial NCT05617677?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 516 participants. The study started on 2023-01-12. Estimated completion is 2028-11-13.

What conditions does trial NCT05617677 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus.

What interventions are being tested in trial NCT05617677?

The interventions under investigation include: Placebo (OTHER), Deucravacitinib (DRUG).

Who is sponsoring clinical trial NCT05617677?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05617677 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Systemic Lupus Erythematosus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Systemic Lupus Erythematosus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.